AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Ligand to Report 2019 Fourth Quarter and Full Year Financial Results on February 6th

January 9, 2020 GMT

SAN DIEGO--(BUSINESS WIRE)--Jan 9, 2020--

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report 2019 fourth quarter and full year financial results on February 6, 2020. Ligand’s CEO John Higgins, President and COO Matt Foehr and Executive Vice President and CFO Matt Korenberg will host the conference call.

2019 Fourth Quarter and Full Year Earnings Conference Call

What:

Ligand conference call to discuss financial results and provide general business updates

 

Date:

Thursday, February 6, 2020

 

Time:

4:30 p.m. Eastern time (1:30 p.m. Pacific time)

 

Conference Call:

Dial (833) 591-4752 within the U.S.

Dial (720) 405-1612 outside the U.S.

Conference ID is 1150048

 

Webcast:

Live conference call webcast and replay accessible at www.ligand.com

About Ligand Pharmaceuticals

Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Our business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company. Our business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation and partnering. We partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) to ultimately generate our revenue. Ligand’s OmniAb technology platform is a patent-protected transgenic animal platform used in the discovery of fully human mono- and bispecific therapeutic antibodies. The Captisol® platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs The Vernalis Design Platform (VDP) integrates protein structure determination and engineering, fragment screening and molecular modeling, with medicinal chemistry, to help enable success in novel drug discovery programs against highly-challenging targets. Ligand has established multiple alliances, licenses and other business relationships with the world’s leading pharmaceutical companies including Amgen, Merck, Sanofi, Pfizer, Janssen, Takeda, Baxter International and Eli Lilly. For more information, please visit www.ligand.com.

Follow Ligand on Twitter @Ligand_LGND.

View source version on businesswire.com:https://www.businesswire.com/news/home/20200109005792/en/

CONTACT: Ligand Pharmaceuticals Incorporated

Patrick O’Brien

Email:investors@ligand.com

Phone: (858) 550-7893

Twitter: @Ligand_LGNDLHA Investor Relations

Bruce Voss

Email:bvoss@lhai.com

Phone: (310) 691-7100

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH

SOURCE: Ligand Pharmaceuticals Incorporated

Copyright Business Wire 2020.

PUB: 01/09/2020 02:47 PM/DISC: 01/09/2020 02:47 PM

http://www.businesswire.com/news/home/20200109005792/en